Loading...
•
Dec 31, 2021
Shattuck Labs Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent business highlights.
Key Takeaways
Shattuck Labs reported fourth quarter revenue of $30.1 million and net income of $7.8 million, or $0.19 per basic share and $0.18 per diluted share. The company's cash, cash equivalents and short-term investments were $268.8 million as of December 31, 2021.
Presented positive initial dose-escalation clinical data for SL-172154, including high target occupancy, dose-dependent immune activation, and unique safety profile in heavily pretreated cancer patients.
Presented positive initial dose-escalation clinical data for SL-279252, including anti-tumor activity, high target occupancy, and dose-dependent immune activation in heavily pretreated cancer patients.
Announced Initial Data from SL-172154 Phase 1 Dose-Escalation Clinical Trial in Platinum- Resistant Ovarian Cancer Demonstrating Favorable Safety Profile, High Target Occupancy, and Unique Pharmacodynamic Activity at the 36th Annual SITC Meeting
Announced Initial Data from Ongoing SL-279252 Phase 1 Dose-Escalation Clinical Trial in Advanced Solid Tumors Demonstrating Evidence of Anti-Tumor Activity and Dose-Dependent Pharmacodynamic Activity at the 36th Annual SITC Meeting
Shattuck Labs
Shattuck Labs
Forward Guidance
Shattuck believes its cash, cash equivalents and short-term investments will be sufficient to fund its operations into the second half of 2024, which is beyond results from its Phase 1 clinical trials of SL-172154 and SL-279252.